Soligenix: Advancing HyBryte™ Toward Commercialization & Expanding Biotech Pipeline

Описание: https://www.soligenix.com Biotech innovation continues to push forward—and Soligenix is advancing a promising treatment while building a diversified pipeline.

At the New York Stock Exchange, Jane King speaks with Soligenix leadership about the company’s lead program, HyBryte™, a novel photodynamic therapy using safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

With the successful completion of a second Phase 3 study, Soligenix is preparing to pursue regulatory approvals and potential commercialization worldwide.

Key Highlights:

🔬 HyBryte™ (Lead Program)
• Novel photodynamic therapy utilizing visible light
• Targeting cutaneous T-cell lymphoma (CTCL)
• Completing confirmatory Phase 3 study with results this year
• Regulatory approvals expected to support global commercialization

🧪 Pipeline Expansion
• Potential expansion of synthetic hypericin into psoriasis
• Development of innate defense regulator technology
• Focusing on inflammatory diseases, including Behçet’s Disease

🌍 Diversified Platform
• Portfolio spans Specialized BioTherapeutics and Public Health Solutions
• Multiple orphan (rare disease) and fast-track programs
• Estimated market potential exceeding $2B globally
• Strategic collaborations with biotech, academia, and government partners

💡 Strategy & Growth
Soligenix is focused on building shareholder value through a combination of clinical success, pipeline diversification, and strategic partnerships, including potential M&A or regional commercialization opportunities.